|
YALE COMPREHENSIVE CANCER CENTER
|
3P30CA016359-33S1
|
$35,000
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
YALE COMPREHENSIVE CANCER CENTER
|
3P30CA016359-33S2
|
$5,000
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
YALE COMPREHENSIVE CANCER CENTER
|
5P30CA016359-33
|
$1,795,225
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-14
|
$330,937
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Wnt antagonist genes in kidney tumor progression and metastasis
|
5R01CA130860-04
|
$603,974
|
DAHIYA, RAJVIR
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
|
Vitamin D Pooling Project
|
ZIA CP010195-10436
|
$75,891
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Virginia Mason Community Clinical Oncology Program
|
2U10CA035192-27A1
|
$569,700
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
VHL Ubiquitin Ligase Activity and Oxygen regulated gene expression
|
5R01CA125930-05
|
$218,948
|
GNARRA, JAMES
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
2R01CA109860-07
|
$328,499
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
Veterans Administration hospitalization database, Patient Treatment File, and Out
|
ZIA CP010126-00580
|
$48,591
|
McGlynn, Katherine
|
DCEG (NCI)
|
|
VCU Minority-Based Community Clinical Oncology Program
|
3U10CA052784-21S1
|
$50,000
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Minority-Based Community Clinical Oncology Program
|
5U10CA052784-21
|
$490,679
|
roberts, john
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Validation of copy number changes by MLPA as predictors of relapse in Wilms tumor
|
1R21CA155556-01
|
$191,835
|
PERLMAN, ELIZABETH
|
CHILDREN'S MEMORIAL HOSPITAL (CHICAGO)
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-38S1
|
$74,970
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-38S2
|
$139,926
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-38
|
$4,555,705
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Urologic Oncology Research Training Grant
|
5T32CA082088-12
|
$254,589
|
SCARDINO, PETER
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Urologic Oncology Branch Consult Core
|
ZID BC 011092
|
$1,932,712
|
Linehan, W. Marston
|
CCR (NCI)
|
|
URINARY BIOMARKERS OF RENAL CELL CARCINOMAS
|
1R01CA141521-01A2
|
$315,400
|
MORRISSEY, JEREMIAH
|
WASHINGTON UNIVERSITY
|
|
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035119-27
|
$1,400,911
|
BEARDEN, JAMES
|
SPARTANBURG REGIONAL MEDICAL CENTER
|
|
Unraveling the roles of VHL and hypoxia-inducible factor in VHL phenotypes
|
2R15CA121992-02A1
|
$283,108
|
SCHOENFELD, ALAN
|
ADELPHI UNIVERSITY
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-27
|
$2,137,632
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Colorado Southwest Oncology Group
|
5U10CA042777-24
|
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
Understanding T Cell Rapamycin Resistance
|
ZIA BC 011220
|
$218,895
|
Fowler, Daniel
|
CCR (NCI)
|
|
U10 Full Member Application Affiliated with SWOG
|
5U10CA105409-08
|
$325,684
|
Kim, Edward
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$195,669
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Tumor Banking for the Southwest Oncology Group
|
3U24CA114748-05S2
|
$124,541
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Translational Surgical Pathology
|
ZIE SC 000853
|
$216,419
|
Merino, Maria
|
CCR (NCI)
|
|
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
|
5R01CA109446-08
|
$260,730
|
Griffith, Thomas
|
UNIVERSITY OF IOWA
|
|
TOPIC 255 SELECTIVE AND POTENT INHIBITORS OF TUMOR SPECIFIC GLUCOSE METABOLISM AS
|
N43CO110091-000
|
$183,071
|
PEARSON, PAUL
|
RUGA CORPORATION
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA035415-28
|
$797,203
|
MOWAT, REX
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-02
|
$188,304
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Tissue Processing/Sequencing Core
|
ZIC BC 011044
|
$399,586
|
Vocke, Cathy
|
CCR (NCI)
|
|
Tissue Array Research Program
|
ZIC BC 010923
|
$528,614
|
Hewitt, Stephen
|
CCR (NCI)
|
|
The von Hippel-Lindau Tumor Suppressor Protein:Roles in Cancer and Oxygen Sensing
|
2R01CA068490-16
|
$292,284
|
KAELIN, WILLIAM
|
DANA-FARBER CANCER INSTITUTE
|
|
The role of the Ras effector Nore1a in tumor suppression
|
5R01CA133171-02
|
$269,911
|
Clark, Geoffrey
|
UNIVERSITY OF LOUISVILLE
|
|
The Role of IKK and NF-kappaB in Controlling mTOR Signaling and TSC Progression
|
1K99CA149178-01A1
|
$82,071
|
Dan, Hancai
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
The Role of Fgf Signaling in Vertebrate Development
|
ZIA BC 010338
|
$298,038
|
Lewandoski, Mark
|
CCR (NCI)
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-18S1
|
$72,130
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-18S2
|
$75,000
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-18
|
$4,829,858
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
5R01CA079830-10
|
$320,196
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
The Gulf Coast MBCCOP
|
5U10CA128536-05
|
$484,872
|
BEEKER, THADDEUS
|
PROVIDENCE HOSPITAL (MOBILE, AL)
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-05S1
|
$49,979
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-05S2
|
$139,741
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
5U10CA114671-05
|
$518,164
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
5R01CA077091-08
|
$1
|
Au, Jessie
|
OPTIMUM THERAPEUTICS, LLC
|
|
TAS::75 0849::TAS INCREMENTAL FUNDING
|
N01CO800001-038
|
$221,493,424
|
HEIMBROOK, DAVID
|
SAIC-FREDERICK, INC.
|
|
Targeting the PI3-Kinase/Akt Pathway for the Therapy of Renal Cell Carcinoma
|
5K08CA142890-03
|
$169,400
|
Cho, Daniel
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Tailored Algorithms for Non-Contrast Computed Tomography Using Sinogram Restorati
|
5R01CA134680-04
|
$261,948
|
LA RIVIERE, PATRICK
|
UNIVERSITY OF CHICAGO
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|